Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31349694 | 1.00 | GLA (0.70) | GLATDP1HDAC3HDAC4HDAC1 | |
| SCHEMBL1374180 | 1.00 | GLA (0.70) | GLATDP1HDAC3HDAC4HDAC1 | |
| SCHEMBL141554 | 0.98 | GLA (0.73) | GLATDP1HDAC3HDAC4HDAC1 | |
| SCHEMBL1105479 | 0.98 | GLA (0.73) | GLATDP1HDAC3HDAC4HDAC1 | |
| SCHEMBL22529691 | 0.98 | GLA (0.73) | GLATDP1HDAC3HDAC4HDAC1 | |
| SCHEMBL10911551 | 0.98 | GLA (0.73) | GLATDP1HDAC3HDAC4HDAC1 | |
| Acetone SCHEMBL11002206 | 0.96 | GLA (0.70) | GLATDP1HDAC3HDAC4HDAC1 | |
| Juarezic Acid SCHEMBL28980693 | 0.84 | HDAC3 (0.63) | GLATDP1HDAC3HDAC4HDAC1 | |
| SCHEMBL15163748 | 0.84 | HDAC3 (0.61) | GLATDP1HDAC3HDAC4HDAC1 | |
| SCHEMBL560055 | 0.83 | HDAC3 (0.68) | GLATDP1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8878169-B2 | Photocurable polymeric materials and related electronic devices | POLYERA CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130200345-A1 | Photocurable Polymeric Materials and Related Electronic Devices | USINVEST LLC | 2013-08-08 | — | — | US | disclosed |
| US-8138225-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138225-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-7842727-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842727-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842727-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7214831-B2 | Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214831-B2 | Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | ERRANT GENE THERAPEUTICS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | ERRANT GENE THERAPEUTICS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | ERRANT GENE THERAPEUTICS, LLC | 2007-02-15 | — | — | US | disclosed |
| EP-1511729-A4 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHACHALCOGENMETHYLCARBONYL COMPOUNDS | ERRANT GENE THERAPEUTICS LLC (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1511729-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHACHALCOGENMETHYLCARBONYL COMPOUNDS | Errant Gene Therapeutics, LLC (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040023944-A1 | Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds | BEACON LABORATORIES, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099272-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETOEPOXIDE COMPOUNDS | ERRANT GENE THERAPEUTICS, LLC (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099789-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHACHALCOGENMETHYLCARBONYL COMPOUNDS | ERRANT GENE THERAPEUTICS, LLC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023944-A1 | Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds | HDAC1, HDAC10, KAT2A | GLA 983/4885TDP1 3668/4885HDAC3 5/4885 |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC6, HDAC5 | GLA 611/4885TDP1 2835/4885HDAC3 6/4885 |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | HDAC5, HDAC1, ZNF277 | GLA 1056/4885TDP1 3352/4885HDAC3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.